Peer-reviewed veterinary case report
Safe vinorelbine dosage and side effects in dogs with cancer
By Poirier, Valerie J et al.Ā·Published in Journal of veterinary internal medicineĀ·2004Ā·Department of Medical Sciences, United StatesĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia.
- Species:
- dog
Plain-English summary
Nineteen dogs with cancer were treated with vinorelbine (Navelbine), a medication given through an IV, to see how well it worked and what side effects it caused. The dogs received between 1 to 11 treatments, and the recommended starting dose was found to be 15 mg/m2. While some dogs experienced a drop in white blood cells (neutropenia), which is a common side effect, two dogs with a specific type of lung cancer showed a partial response to the treatment. One of these dogs is still alive more than two years later, suggesting that vinorelbine may be a promising option for treating certain cancers in dogs.
People also search for: dog cancer treatment vinorelbine Ā· side effects of Navelbine in dogs Ā· dog lung cancer prognosis
Abstract
The purpose of this study was to evaluate short-term adverse effects and determine a safe dosage for vinorelbine (Navelbine)--a new semisynthetic vinca alkaloid--in dogs with malignant tumors. Nineteen dogs were treated with vinorelbine as a 5-minute IV infusion every 7 days at starting dosages ranging from 10 to 20 mg/m2. The median number of treatments per dog was 7 (range, 1-11). The maximum tolerated dosage varied between 15 and 18 mg/m2, and a starting dosage of 15 mg/m2 is recommended. Neutropenia was the dose-limiting toxicity. Although efficacy was a secondary endpoint of this dosage-finding study, 2 dogs with metastatic bronchoalveolar carcinoma experienced a partial response for an overall response rate of 12.5% in 16 dogs with gross measurable disease. Three dogs with microscopic disease were treated (incompletely excised bronchoalveolar carcinoma or lymph node metastatic disease). Two died of pulmonary metastatic disease 113 and 196 days posttreatment, and 1 is still alive after at least 730 days. The well-tolerated toxicity profile and clinical activity observed in dogs with bronchoalveolar carcinoma warrants further investigation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15320594/